Company Profile

12:11 PM EDT, 04/15/21
Last: $5.32 Change: +0.16 %Change: +3.09% Volume: 100
Detailed Quote
Open: $ 5.32   Volume: 100
High: $ 5.32   Yield(%) n/a
Low: $ 5.32   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 185,356.74
EPS ($) n/a   Shares Out: 34,711.00
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): n/a
% Price Change (last 13 weeks): n/a
% Price Change (last 26 weeks): n/a
% Price Change (last 52 weeks): n/a
% Price Change (year to date): n/a
Management Effectiveness
Return on Equity (%): n/a
Return on Assets (%): n/a
Return on Invested Capital (%): n/a
Gross Profit Margin (%): n/a
Net Profit Margin (%): n/a
Operating Profit Margin (%): n/a
Price & Volume
50-day Moving Average: $2.85
200-day Moving Average: $n/a
Avg. Daily Vol. (last 50 days): 325
Avg. Daily Vol. (last 200 days): n/a
52-wk high: $9.00
52-wk low: $4.76
Bid: $n/a
Ask: $n/a
Company Information
Orexo AB is engaged in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. Its pipeline comprises of Zubsolv, Abstral, Edluar, Zubsolv, OX51, OX-MP1, and OX382. The company was founded by Thomas Lundqvist, Anders Pettersson, and Lars Christer Nyström on November 18, 1994 and is headquartered in Uppsala, Sweden.
Orexo AB
Rapsgatan 7e
Uppsala UP 751 05

Phone: 46.18.780.88.00
Fax: 46.18.780.88.88
Per Share Data
Earnings (1year) ($): n/a
Annual Dividend ($): n/a
Current P/E Ratio (ttm): n/a
Book Value ($): n/a
Cash Flow ($): n/a
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): n/a
Price/Book (x): n/a
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): n/a
Current Ratio (x): n/a
LT Debt/Equity (x): n/a
Total Debt/Equity (x): n/a

Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.